Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and patient-important outcomes.

The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.

In addition to the Official Singles and Albums Chart, did you know the Official Charts Company compiles 50+ charts every week, spanning different genres and formats? Explore them all here.

Professor Richard Scolyer, the renowned scientist co-named Australian of the Year, has made a huge announcement about his future at the Melanoma Institute of Australia. A review of trans healthcare ...